Update on management of paediatric dyslipidaemia.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2023-02-01 DOI:10.1097/MED.0000000000000794

Nidhi Bansal, Seema Kumar, Preneet Cheema Brar

{"title":"Update on management of paediatric dyslipidaemia.","authors":"Nidhi Bansal, Seema Kumar, Preneet Cheema Brar","doi":"10.1097/MED.0000000000000794","DOIUrl":null,"url":null,"abstract":"Purpose of review: Atherosclerosis and associated cardiovascular risk factors originate in childhood; hence, early management of dyslipidaemia is vital. However, hypercholesterolemia remains untreated or undertreated in many youths. We review current therapies, drugs under investigation and consider potential future directions for the management of paediatric dyslipidaemia to highlight the recent evidence and new therapeutic options for future use.Recent findings: Cardiovascular disease (CVD) risk factors in childhood, including dyslipidaemia, are associated with CVD risk and clinical CVD events in adulthood. Recent data show that initiation of statin therapy in childhood in children with familial hypercholesterolemia reduces the risk of CVD in adulthood. Several well tolerated and efficacious treatment options have become available in recent times for the management of dyslipidaemia in youth. Many new lipid-lowering drugs are under investigation to widen the available choices. Some of these drugs are now available for use in paediatrics, while some remain targets for future use.Summary: We review available treatment options for paediatric dyslipidaemia management, discuss potential limitations and propose future directions. We also acknowledge the need for continued research in paediatrics for optimal paediatric dyslipidaemia management.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 1","pages":"52-64"},"PeriodicalIF":2.6000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrinology & Diabetes and Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MED.0000000000000794","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 3

Abstract

Purpose of review: Atherosclerosis and associated cardiovascular risk factors originate in childhood; hence, early management of dyslipidaemia is vital. However, hypercholesterolemia remains untreated or undertreated in many youths. We review current therapies, drugs under investigation and consider potential future directions for the management of paediatric dyslipidaemia to highlight the recent evidence and new therapeutic options for future use.

Recent findings: Cardiovascular disease (CVD) risk factors in childhood, including dyslipidaemia, are associated with CVD risk and clinical CVD events in adulthood. Recent data show that initiation of statin therapy in childhood in children with familial hypercholesterolemia reduces the risk of CVD in adulthood. Several well tolerated and efficacious treatment options have become available in recent times for the management of dyslipidaemia in youth. Many new lipid-lowering drugs are under investigation to widen the available choices. Some of these drugs are now available for use in paediatrics, while some remain targets for future use.

Summary: We review available treatment options for paediatric dyslipidaemia management, discuss potential limitations and propose future directions. We also acknowledge the need for continued research in paediatrics for optimal paediatric dyslipidaemia management.

查看原文本刊更多论文

儿科血脂异常管理的最新进展。

回顾目的:动脉粥样硬化及相关心血管危险因素起源于童年;因此，早期处理血脂异常是至关重要的。然而，在许多年轻人中，高胆固醇血症仍未得到治疗或治疗不足。我们回顾了目前的治疗方法、正在研究的药物，并考虑了儿科血脂异常管理的潜在未来方向，以突出最近的证据和未来使用的新治疗方案。近期研究发现:儿童期心血管疾病(CVD)危险因素，包括血脂异常，与成年期CVD风险和临床CVD事件相关。最近的数据显示，患有家族性高胆固醇血症的儿童在儿童期开始他汀类药物治疗可降低成年期心血管疾病的风险。近年来，一些耐受性良好且有效的治疗方案可用于治疗青少年血脂异常。许多新的降脂药物正在研究中，以扩大可用的选择。其中一些药物现在可用于儿科，而一些仍是未来使用的目标。总结:我们回顾了儿科血脂异常管理的现有治疗方案，讨论了潜在的局限性并提出了未来的发展方向。我们也承认需要继续在儿科进行研究，以获得最佳的儿科血脂异常管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Endocrinology & Diabetes and Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.80

自引率

3.10%

发文量

128

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Endocrinology, Diabetes and Obesity delivers a broad-based perspective on the most recent and exciting developments in the field from across the world. Published bimonthly and featuring twelve key topics – including androgens, gastrointestinal hormones, diabetes and the endocrine pancreas, and neuroendocrinology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.